JP2022519082A5 - - Google Patents
Info
- Publication number
- JP2022519082A5 JP2022519082A5 JP2021544622A JP2021544622A JP2022519082A5 JP 2022519082 A5 JP2022519082 A5 JP 2022519082A5 JP 2021544622 A JP2021544622 A JP 2021544622A JP 2021544622 A JP2021544622 A JP 2021544622A JP 2022519082 A5 JP2022519082 A5 JP 2022519082A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody according
- sequence
- human
- multispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024218893A JP2025032324A (ja) | 2019-02-01 | 2024-12-13 | 新規ｃｄ４０結合抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2022494 | 2019-02-01 | ||
| NL2022494A NL2022494B1 (en) | 2019-02-01 | 2019-02-01 | Novel CD40-binding antibodies |
| NL2024087 | 2019-10-23 | ||
| NL2024087 | 2019-10-23 | ||
| PCT/NL2020/050051 WO2020159368A1 (en) | 2019-02-01 | 2020-01-30 | Novel cd40-binding antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024218893A Division JP2025032324A (ja) | 2019-02-01 | 2024-12-13 | 新規ｃｄ４０結合抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022519082A JP2022519082A (ja) | 2022-03-18 |
| JP2022519082A5 true JP2022519082A5 (https=) | 2022-12-27 |
Family
ID=71840475
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544622A Pending JP2022519082A (ja) | 2019-02-01 | 2020-01-30 | 新規ｃｄ４０結合抗体 |
| JP2024218893A Ceased JP2025032324A (ja) | 2019-02-01 | 2024-12-13 | 新規ｃｄ４０結合抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024218893A Ceased JP2025032324A (ja) | 2019-02-01 | 2024-12-13 | 新規ｃｄ４０結合抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220135694A1 (https=) |
| EP (1) | EP3917960A1 (https=) |
| JP (2) | JP2022519082A (https=) |
| KR (1) | KR20210141466A (https=) |
| CN (1) | CN113993893A (https=) |
| AU (1) | AU2020216250A1 (https=) |
| BR (1) | BR112021015238A8 (https=) |
| CA (1) | CA3128148A1 (https=) |
| MX (1) | MX2021009285A (https=) |
| SG (1) | SG11202108141VA (https=) |
| WO (1) | WO2020159368A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230042035A (ko) | 2020-07-08 | 2023-03-27 | 라바 테라퓨틱스 엔.브이. | Psma와 감마-델타 t 세포 수용체에 결합할 수 있는 항체 |
| PL4269444T3 (pl) * | 2020-08-14 | 2025-01-13 | GammaDelta Therapeutics Limited | Wieloswoiste przeciwciała anty-tcr zmienne delta 1 |
| CA3200826A1 (en) * | 2020-12-10 | 2022-06-16 | Paul Willem Henri Ida PARREN | Antibodies that bind gamma-delta t cell receptors |
| AU2022224391A1 (en) * | 2021-02-17 | 2023-08-24 | Gammadelta Therapeutics Ltd | Anti-tcr delta variable 1 antibodies |
| MX2023009544A (es) | 2021-02-17 | 2023-11-28 | Gammadelta Therapeutics Ltd | Anticuerpos anti-variable delta 1 de tcr multiespecíficos. |
| JP2024523316A (ja) | 2021-06-18 | 2024-06-28 | オートラス リミテッド | Ｃａｒ ｔ細胞における、および疾患の処置のための抗ｃｄ３０７ｅ単一ドメイン抗体、その使用 |
| AU2022332499A1 (en) * | 2021-08-24 | 2024-03-21 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Fap/cd40 binding molecule and medicinal use thereof |
| TW202328197A (zh) * | 2021-09-24 | 2023-07-16 | 大陸商正大天晴藥業集團股份有限公司 | 抗cd40抗體及其用途 |
| JP2024538958A (ja) | 2021-10-21 | 2024-10-28 | ラヴァ・セラピューティクス・エヌ・ヴイ | ガンマデルタｔ細胞活性化抗体の使用 |
| JP2025504363A (ja) * | 2022-01-05 | 2025-02-12 | インヒブルクス バイオサイエンシズ インコーポレイテッド | γδＴ細胞結合ポリペプチド及びその使用 |
| CA3208653A1 (en) * | 2022-02-17 | 2022-08-25 | Mihriban Tuna | Multispecific anti-tcr delta variable 1 antibodies |
| EP4292609A1 (en) * | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Compositions comprising antibodies that bind gamma-delta t cell receptors |
| EP4292610A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
| CN119768433A (zh) * | 2022-06-28 | 2025-04-04 | 珠海烁星生物医药科技有限公司 | 单特异性和多特异性抗体 |
| CN116023495B (zh) * | 2022-09-05 | 2023-10-03 | 上海百英生物科技股份有限公司 | 一种抗cd40纳米抗体及其制备方法与应用 |
| WO2024092150A2 (en) * | 2022-10-26 | 2024-05-02 | Providence Health & Services - Oregon | Combination therapies utilizing microbially-expanded gamma delta t cells and t cell engaging biologics |
| WO2025184603A2 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| US20250276092A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| KR20260004605A (ko) * | 2024-07-01 | 2026-01-09 | 주식회사 피비이뮨테라퓨틱스 | 길항성 항-cd40 인간화 항체 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1322383B9 (en) * | 2000-10-02 | 2006-09-06 | Chiron Corporation | Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| CA2631184A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| WO2010059315A1 (en) | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| WO2010111625A1 (en) | 2009-03-27 | 2010-09-30 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
| CN103261220B (zh) | 2010-08-16 | 2016-06-15 | 诺夫免疫股份有限公司 | 用于生成多特异性和多价抗体的方法 |
| HUE038848T2 (hu) * | 2011-04-21 | 2018-11-28 | Bristol Myers Squibb Co | CD40-antagonista antitest polipeptidek |
| US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
| DK2924052T3 (da) | 2012-11-21 | 2019-09-30 | Pharmabcine Inc | Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme |
| DK3129404T3 (da) | 2014-04-10 | 2026-04-20 | Lava Therapeutics N V | Immunglobuliner, der binder humane vgamma9vdelta2-t-cellereceptorer |
| WO2018011421A1 (en) * | 2016-07-14 | 2018-01-18 | Genmab A/S | Multispecific antibodies against cd40 and cd137 |
| US11220550B2 (en) * | 2017-05-25 | 2022-01-11 | Bristol-Myers Squibb Company | Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity |
-
2020
- 2020-01-30 CN CN202080018185.2A patent/CN113993893A/zh active Pending
- 2020-01-30 EP EP20703313.5A patent/EP3917960A1/en active Pending
- 2020-01-30 MX MX2021009285A patent/MX2021009285A/es unknown
- 2020-01-30 JP JP2021544622A patent/JP2022519082A/ja active Pending
- 2020-01-30 SG SG11202108141VA patent/SG11202108141VA/en unknown
- 2020-01-30 KR KR1020217027592A patent/KR20210141466A/ko not_active Ceased
- 2020-01-30 CA CA3128148A patent/CA3128148A1/en active Pending
- 2020-01-30 US US17/427,291 patent/US20220135694A1/en not_active Abandoned
- 2020-01-30 WO PCT/NL2020/050051 patent/WO2020159368A1/en not_active Ceased
- 2020-01-30 BR BR112021015238A patent/BR112021015238A8/pt unknown
- 2020-01-30 AU AU2020216250A patent/AU2020216250A1/en active Pending
-
2024
- 2024-12-13 JP JP2024218893A patent/JP2025032324A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022519082A5 (https=) | ||
| JP5723279B2 (ja) | 抗ｃｘｃｒ４抗体および癌治療のためのそれらの使用 | |
| CN101939336B (zh) | Axl抗体 | |
| US9150657B2 (en) | Anti-EPHA2 antibody | |
| JP2021508469A5 (https=) | ||
| TWI854953B (zh) | 抗ｃｄ３抗體及含有該抗體的分子、及其製造方法 | |
| CA3168654A1 (en) | Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine | |
| EP3020812B1 (en) | Novel anti-dr5 antibody | |
| JP2018503380A5 (https=) | ||
| CN103189392B (zh) | ErbB3结合抗体 | |
| EP3645742A2 (en) | Anti-ror1 antibodies and methods of making and using thereof | |
| JP2020501531A5 (https=) | ||
| HRP20150256T1 (hr) | Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe | |
| WO2016179335A1 (en) | Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof | |
| JP2010532169A5 (https=) | ||
| JP2018502050A5 (https=) | ||
| JP2009545325A5 (https=) | ||
| CN116041530A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2020516309A5 (https=) | ||
| WO2020156555A1 (zh) | 抗her2的双特异性抗体及其应用 | |
| JP2024533457A5 (https=) | ||
| EP4242231A1 (en) | Anti-siglec-15 antibody and application thereof in preparing drug | |
| WO2015084736A4 (en) | Antibodies targeting b-cell receptor complex membrane bound igm and uses thereof | |
| HK40018991A (en) | Multi-specific antibodies and methods of making and using thereof | |
| NZ739252A (en) | Monoclonal antibodies against bcma |